Source: CV Sciences, Inc.
Company Addresses its Lead Drug Candidate Aimed at a $2B Market Opportunity
Management of CV Sciences, Inc. (OTCQB: CVSI)
(the "Company", "CV Sciences", "our" or "we"), commented today
regarding the U.S. Department of Defense's (DoD's) recent campaign to
provide assistance to military personnel looking to quit the use of
smokeless tobacco.
Earlier this year, the DoD launched a website and support program called the "Great American Spit-Out" at UcanQuit2.org
to assist servicemen and women in quitting the use of harmful smokeless
tobacco products. The "Great American Spit-Out" webpage on the DoD
website offered referrals across the U.S. to local support groups and an
opportunity for visitors to chat instantly with an online tobacco
cessation coach to provide free counseling to help people deal with
their addiction.
"We greatly appreciate the U.S. Department of
Defense bringing not only awareness but offering solutions available to
the public through the UcanQuit2.org website," explained Michael Mona,
Jr., President and CEO of CV Sciences. "The DoD recognizes the same
problem that we identified during the development of our smokeless
tobacco cessation product. The DoD clearly indicates that by quitting
smokeless tobacco, you can 'drop the risk for developing cancer of the
cheek, gums, and inner surface of the lips.' We strongly believe that
highlighting these examples is critical as we at CV Sciences are
addressing a massive unmet medical need in the treatment of smokeless
tobacco addiction. Currently, there are no FDA-approved drugs to treat
this widespread and deadly addiction. Our lead drug candidate, CVSI-007,
is aimed at addressing this huge unmet need. We estimate that the
current treatment market in the U.S. alone is greater than $2 billion."
The DoD's site lists the dangers of smokeless tobacco and provides support resources here:
https://ucanquit2.org/Events/2017/Great-American-Spit-Out-2017.aspx
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI)
operates two distinct business segments: a drug development division
focused on developing and commercializing novel therapeutics utilizing
synthetic CBD; and, a consumer product division in manufacturing,
marketing and selling plant-based CBD products to a range of market
sectors. CV Sciences, Inc. has primary offices and facilities in San
Diego, California and Las Vegas, Nevada. Additional information is
available from OTCMarkets.com or by visiting www.cvsciences.com.
No comments:
Post a Comment